Fig. 4
Nocodazole does not ameliorate the effect of reduced spast activity on spinal motor axon outgrowth. Embryos were microinjected with 0.4 pmol of spg4atg1 morpholino and continuously exposed to nocodazole at the concentrations indicated from 24 hpf to 30 hpf, prior to fixation and immunostaining with znp-1. Representative images are shown of an untreated uninjected embryo (A); an uninjected embryo treated with 0.5 μg/ml nocodazole (B); a spast-morphant embryo treated with DMSO vehicle (C); a spast-morphant embryo treated with 0.1 μg/ml nocodazole (D); a spast-morphant embryo treated with 0.3 μg/ml nocodazole (E); and a spast-morphant embryo treated with 0.5 µg/ml nocodazole (F). Scale bars: 50 μm.